Rivia

Name: Rivia
Brand: Rivia

AI Native

Know better. Act better.

Est 2022|Valuation $67M|Raised $18.8M|11 Ref Customers

LinkedIn 4K|Web traffic 2K|FTEs 20|HQ Zurich, Switzerland

MarketsNL & Conversational Analytics

01Competitive Landscape

Narrative analysis: where alternatives may excel

IQVIA: - Strong fit if a sponsor already uses IQVIA clinical technology and seeks consistent governance and enterprise support. - Offers modular clinical data ingestion/review/analytics described publicly. Saama: - Positions itself with deep AI/ML model experience and publishes operational impact claims. May be a fit for organizations seeking a broader AI analytics partnership with established pharma references. Veeva / Medidata: - Often selected when the priority is platform standardization across the clinical stack (CTMS/eTMF/EDC and adjacent processes). - Can reduce integration complexity inside a single ecosystem, although customers sometimes cite cost and vendor lock-in concerns.

Adoption / market trends

The broader market is moving toward data unification layers, AI-assisted review, and reduced manual reconciliation. Large incumbents are launching AI-enabled modules, which increases competitive pressure on newer entrants to differentiate on integration speed, usability, and verifiable outcomes.

	Rivia (official product overview and feature pages)	IQVIA Clinical Data Review / CDAS	Saama (vendor product pages)
Starting Price	Not publicly listed (demo-led)	Not publicly listed (enterprise)	Not publicly listed (demo-led)
Best For	Clinical-stage biotechs/pharma sponsors needing relatively rapid integration and AI-assisted exploration	Enterprises/CROs wanting an integrated data analytics suite within the IQVIA ecosystem	Sponsors seeking a broad AI/analytics partner with an established set of references
Key Strength	Vendor-stated quick integration with SDTM-oriented mapping and natural-language visual analytics	Broad clinical technology footprint; integrated workflows and modules	Longstanding focus on AI in life sciences and vendor-published quantified claims
Key Weakness	Limited independent reviews/public proof; unknown scalability/pricing for large programs	Perception of high cost and enterprise complexity (common in large vendors)	Enterprise-oriented; vendor-published claims require validation

01Competitive Landscape

Narrative analysis: where alternatives may excel

IQVIA:

Strong fit if a sponsor already uses IQVIA clinical technology and seeks consistent governance and enterprise support.
Offers modular clinical data ingestion/review/analytics described publicly.

Saama:

Positions itself with deep AI/ML model experience and publishes operational impact claims. May be a fit for organizations seeking a broader AI analytics partnership with established pharma references.

Veeva / Medidata:

Often selected when the priority is platform standardization across the clinical stack (CTMS/eTMF/EDC and adjacent processes).
Can reduce integration complexity inside a single ecosystem, although customers sometimes cite cost and vendor lock-in concerns.

Adoption / market trends

	Rivia (official product overview and feature pages)	IQVIA Clinical Data Review / CDAS	Saama (vendor product pages)
Starting Price	Not publicly listed (demo-led)	Not publicly listed (enterprise)	Not publicly listed (demo-led)
Best For	Clinical-stage biotechs/pharma sponsors needing relatively rapid integration and AI-assisted exploration	Enterprises/CROs wanting an integrated data analytics suite within the IQVIA ecosystem	Sponsors seeking a broad AI/analytics partner with an established set of references
Key Strength	Vendor-stated quick integration with SDTM-oriented mapping and natural-language visual analytics	Broad clinical technology footprint; integrated workflows and modules	Longstanding focus on AI in life sciences and vendor-published quantified claims
Key Weakness	Limited independent reviews/public proof; unknown scalability/pricing for large programs	Perception of high cost and enterprise complexity (common in large vendors)	Enterprise-oriented; vendor-published claims require validation